March 31, 2008 -- Sinovac Biotech (AMEX: SVA) reported that revenues jumped 118% in 2007 to $33.5 million while net profit came in at $7.7 million against a small loss a year ago. The profit is equal to 19 cents per share. The company markets Healive®, an inactivated hepatitis A vaccine, and Anflu®, a seasonal influenza vaccine. Sales of Anflu jumped from 77,000 doses in 2006 to 1.6 million doses in 2007, while sales for Healive almost doubled, moving up from 2.6 million doses in 2006 to 5.1 million doses in 2007. More details...
